Eve Health Group Limited. (EVE) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
Google NewsEVE Health Group (ASX: EVE): Shares Gain as Commercial Pharma Strategy Moves Forward - Kalkine
EVE Health Group (ASX: EVE): Shares Gain as Commercial Pharma Strategy Moves Forward Kalkine
Appendix 4G and Corporate Governance Statement
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report - Amended
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Change of Director's Interest Notice x 3
director_dealing announcement
Small CapsEve Initiates Pilot Clinical Study for Libbo ED Film
other announcement
'Too risky': Blues dealt injury blow on eve of Origin Game I
The NSW Blues have confirmed five-eighth Mitchell Moses will miss Wednesday night's State of Origin opener due to a hamstring injury.
KalkineWhat’s Driving the Leadership Shift at (ASX:EVE)?
Highlights Leadership reshuffle aligns with growth strategy Focus shifts toward faster product commercialisation Drug reformulation approach gains strategic emphasis A leadership transition at (ASX:EVE) signals a sharper focus on commercial execution, regulatory advancement, and innovative drug reformulation aimed at strengthening its healthcare portfolio. Within the broader landscape of healthcare innovation and ASX 200, companies are increasingly refining leadership structures to alig...
EVE Share Expansion: What It Signals for Market Trends
Highlights Capital expansion signals shifting liquidity dynamics Market focus turns to share structure changes Sentiment driven by evolving trading activity EVE Health Group’s expanded share base highlights how capital structure changes influence liquidity, ownership, and sentiment across Australia’s evolving equity market landscape. Australia’s market for position-driven trading continues to reveal how sentiment and capital flows shape short-term behaviour, particular...
EVE Health Expands Reformulated Drug Development Strategy
Highlights Capital raise supports reformulated pharmaceutical pipeline Focus on improved drug delivery and patient convenience Strategy targets global therapeutic markets EVE Health Group strengthens its pharmaceutical reformulation strategy through fresh capital aimed at advancing drug delivery technologies, intellectual property development, and regulatory progress across global therapeutic segments. EVE Health Strengthens Reformulated Drug Strategy EVE Health Group Raises $0.9m to Ad...
EVE Raises $0.9m to Advance Drug Reformulation Strategy
other announcement
EVE Advances Reformulated Drugs Targeting Global Markets
other announcement
Sama Balasubramanian Appointed to Scientific Advisory Board
other announcement
Launch of Libbo and Activation of Men's Health Platform
other announcement
Change of Director's Interest Notice x 3
director_dealing announcement